Organization
Little Rock, AR
6 abstracts
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.Org: University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,
Abstract
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).Org: Medical College of Wisconsin, Milwaukee, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Arkansas Medical Sciences,
Abstract
Altmetrics of breast cancer clinical trials’ subgroup analysis: A systematic review.Org: University of Jordan, Amman, Jordan, Jordan University of Science and Technology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,
Abstract
Use of secondary subgroup analysis of clinical trials across solid malignancies.Org: Medical School of University, the university of Jordan, Amman, Jordan, University of Jordan, University of Arkansas for Medical Sciences (UAMS),
Abstract
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows.Org: University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,